Related Experiment Video
Updated: Mar 20, 2026

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
Published on: January 4, 2018
A Multicentre, Randomised, Controlled, Open-Label Study of Continuous Subcutaneous Insulin Infusion Plus
Zhenxing Huang1, Yingling Wu1, Chaoyan Tang1,2
1Department of Endocrinology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Aim:
This study evaluated the efficacy and safety of henagliflozin plus continuous subcutaneous insulin infusion (CSII) in treating type 2 diabetes mellitus (T2DM).
Methods:
In this 7-day, multicentre, randomised, open-label, controlled, parallel-group study, 210 adults with T2DM who had been diagnosed within the past 2 years were randomly assigned in a 1:1 ratio to either the henagliflozin combined with CSII group or the CSII group. The primary endpoint was the time in the range (%TIR) of 3.9-10.0 mmol/L blood glucose. The secondary endpoints included (a) the time to achieve the target glucose level (TIR > 70%); (b) mean amplitude of glycaemic excursions (MAGE); (c) time below range (TBR); (d) time above range (TAR); and (e) insulin dosage.
Results:
The TIR was significantly greater in the henagliflozin+CSII group than in the CSII group (79.85% vs. 74.06%; p = 0.005). The time to achieve the target glucose level was shorter in the henagliflozin+CSII group than in the CSII group. The TAR, insulin dosage, mean glucose (MG) and glucose management indicator (GMI) in the henagliflozin+CSII group were significantly lower than those in the CSII group. The TBR, MAGE, coefficient of variation (CV) and mean of daily differences (MODD) were not significantly different between the two groups. Additionally, adverse events such as urinary tract infection, diabetic ketoacidosis and hypoglycaemic events did not differ between the two groups.
Conclusions:
Henagliflozin + CSII achieved better glycaemic control, reduced insulin dosages and had a comparable safety profile versus CSII alone in severely hyperglycaemic T2DM patients.
Trial Registration:
ClinicalTrials.gov NCT05677334.
More Related Videos
04:09Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers
Published on: March 3, 2023
06:13Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
Published on: December 1, 2023
Related Concept Videos
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Diabetes Mellitus: Type 2 and Gestational
Oral Hypoglycemic Agents: Glinides